"目录号: HY-13653
Cell Cycle/DNA DamageEpigeneticsAutophagy-
(-)-Epigallocatechin Gallate 是一种天然的多酚黄酮类化合物，能够抑制telomerase和DNA methyltransferase的活性，同时阻止 EGF 受体和 HER-2 受体活化。
TelomeraseDNA MethyltransferaseAutophagy
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
(-)-Epigallocatechin Gallate is an antioxidant polyphenol flavonoid that inhibitstelomeraseandDNA methyltransferase, and blocks the activation of EGF receptors and HER-2 receptors.
In Vitro
Epigallocatechin Gallate (10 μM, 40 μM, 60 μM) decreases FB-2 and WRO cell proliferation in a dose dependent manner. Epigallocatechol Gallate reduces basal3H Thymidine incorporation in a dose dependent manner reaching 78% inhibition at the concentration of 60 μM. decreases cyclin D1 and up-regulates p21WAF1/Cip1and p53 expression in FB-2 cells[1]. Epigallocatechol Gallate inhibits the proliferation of the cells studied when the concentration is increased and that the inhibition is time dependent. The expression of HES1 in the cell lines treated with 35 μg/mL epigallocatechol gallate is significantly lower than in the control group[2]. In the presence of epigallocatechin gallate aggregation is delayed, cells do not stream and development is typically stalled at the loose aggregate stage[3]. Epigallocatechol Gallate treatment is found to modify the expressions of some of the miRNAs in human hepatocellular carcinoma HepG2 cells, 13 are up-regulated and 48 are down-regulated. miR-16 is one of the miRNAs up-regulated by epigallocatechol gallate and one of its target genes is confirmed to be the anti-apoptotic protein Bcl-2. Epigallocatechol Gallate treatment induces apoptosis and down-regulates Bcl-2 in HepG2 cells[4].
In Vivo
Epigallocatechol Gallate (5 and 20 mg/kg, p.o.) inhibits the growth of tumor in the subcutaneous orthotopic transplant model[2].
Clinical Trial
Seoul National University Hospital
Acne Vulgaris
July 2005
National Health Research Institutes, Taiwan-Mackay Memorial Hospital-Taichung Veterans General Hospital-National Cheng-Kung University Hospital-Chang Gung Memorial Hospital-China Medical University Hospital-National Taiwan University Hospital
NPC
April 2013
Phase 2-Phase 3
Shandong Cancer Hospital and Institute
Breast Neoplasms-Dermatitis-Prevention & Control-Epigallocatechin Gallate
February 2015
Phase 2
Dr. Johannes Levin-German Center for Neurodegenerative Diseases (DZNE)-Deutsche Parkinson Vereinigung-Deutsche Stiftung Neurologie-ParkinsonFonds Deutschland gGmbH-Ludwig-Maximilians - University of Munich
Multiple System Atrophy
January 2014
Phase 3
National Yang Ming University-Taipei City Hospital
Acne Lesion Counts
October 2012
Shandong Cancer Hospital and Institute
Lung Neoplasms-Esophagitis-Prevention & Control-Epigallocatechin Gallate
June 2015
Phase 2
University of Maryland
Hypertension-Obesity-Type 2 Diabetes-Insulin Resistance
February 2007
Phase 2
Maastricht University Medical Center-DSM Nutritional Products, Inc.
Obesity-Type 2 Diabetes Mellitus
October 2008
Parc de Salut Mar
Down Syndrome
May 2010
Phase 2
The University of Texas Health Science Center at San Antonio
Colon Cancer
November 2016
Northumbria University
Cognitive Function-Mood
August 2009
Phase 4
Charite University, Berlin, Germany
Huntington Disease
September 2011
Phase 2
Charite University, Berlin, Germany
Cardiovascular Diseases
August 2012
Hadassah Medical Organization
Cystic Fibrosis
November 1, 2011
IRCCS Policlinico S. Matteo
Primary Amyloidosis of Light Chain Type
January 2012
Phase 2
Parc de Salut Mar
Down Syndrome (DS)
February 2012
Phase 2
Florian Michel-German Federal Ministry of Education and Research-University Hospital Heidelberg
Light Chain (AL) Amyloidosis-Cardiac Involvement
April 2013
Phase 2
Parc de Salut Mar
Fragile X Syndrome
June 11, 2013
University of North Carolina, Chapel Hill-National Center for Complementary and Integrative Health (NCCIH)-National Institutes of Health (NIH)
Chronic Hepatitis C-Oxidative Stress
November 2009
Phase 1
Charite University, Berlin, Germany-TAIYO EUROPE
Multiple Sclerosis
May 2009
Phase 2-Phase 3
National Nutrition and Food Technology Institute-Tehran University of Medical Sciences
Traumatic Brain Injury
March 2015
Phase 2-Phase 3
Meharry Medical College
Leiomyoma
December 2010
Phase 2
Shandong Cancer Hospital and Institute
Epigallocatechin Gallate-Radio Dermatitis-Radiation Mucositis
September 2011
Phase 1-Phase 2
Maastricht University Medical Center
Healthy
August 2012
Taipei City Hospital-National Yang Ming University
Diabetes Mellitus-Hyperlipidemia
May 2012
Phase 2-Phase 3
University of Copenhagen-Unilever R&D
Obesity
November 2005
Charite University, Berlin, Germany
Multiple Sclerosis, Relapsing-Remitting
July 2011
Louisiana State University Health Sciences Center Shreveport-Polyphenon Pharma
Prostate Cancer
May 2004
Phase 2
Chinese University of Hong Kong
Endometriosis
December 8, 2016
Phase 2
Xuanwu Hospital, Beijing-Ministry of Health, China-Michael J. Fox Foundation for Parkinson's Research
Parkinson's Disease
April 2006
Phase 2
Maastricht University Medical Center
Obesity
June 2012
University of California, Davis-Mars, Inc.
Healthy
August 2016
View MoreCollapse
References
